Participants recorded their experience of nausea, vomiting, use of rescue medications, and numbers of doses of study treatment in a diary for days –1 to day 5 of each cycle. The aim of this randomized, placebo-controlled, two-stage, phase II/III trial was to determine the efficacy of an oral cannabis extract in adults with refractory nausea and/or vomiting during moderately or highly emetogenic, intravenous chemotherapy despite guideline-consistent antiemetic prophylaxis. The primary measure of effect was the difference in the proportions of participants with no vomiting or retching and no use of rescue medications (a complete response) during hours after the first cycle of chemotherapy on study (cycle A). The estimated sample size for the pilot trial is 80 patients (40 per arm), using a primary endpoint of complete response to the study drug and placebo during cycle A and B of treatment. Chemotherapy-induced nausea and vomiting (CINV) remains an important issue for patients receiving chemotherapy despite guideline-consistent antiemetic therapy. Cannabinoids, particularly THC and CBD, have demonstrated efficacy in managing neuropathic pain, which is often resistant to conventional analgesics. Cannabinoids have gathered significant attention for their potential therapeutic applications in various neurological disorders. Furthermore, the modulation of endorphins and endocannabinoid receptors by ibuprofen may help preserve appetite during illness, particularly in children . Nausea and vomiting are common and distressing adverse events of chemotherapy. Luckily Jeff at @vitalitycbd sent us some CBD Full Spectrum Oil, Delta 8 THC Oil, (COMPLETELY TASTELESS!!!) some Lemongrass CBD Salve, Delta 8 THC Flower, & some carts. Preclinical and clinical research indicates that CBD has a wide range of therapeutic effects, and many of them are relevant to the management of cancer. Only 10% of participants were treated with olanzapine, which has recently been added to clinical practice guidelines for antiemetic prophylaxis in highly emetogenic chemotherapy. Similar beneficial effects were observed for absence of significant nausea, use of rescue medications, daily vomits, and the nausea scale on the Functional Living Index-Emesis quality-of-life questionnaire. The study recruited 147 evaluable participants out of a planned 250 between 2016 and 2022. The study, conducted across 17 sites in Australia, was funded by the Department of Health, New South Wales Government, with study treatments supplied by Tilray. A comprehensive comparison of previous literature and the current study is summarized and presented in Table 4. The side effects of CX, namely sedation, dizziness, anxiety, dry mouth, confusion, palpitations, hallucination, rash, mood, or behavior changes are presented in Table 3. Sedation and dizziness were major side effects (88.8% 48/54). After exclusion, 54 cases were included in the study. The study was conducted at the Gynecologic Oncology Units, Bhumibol Adulyadej Hospital (BAH), Royal Thai Air Force, Bangkok, Thailand, between August and November 2022. • Cannabinoids have shown antineoplastic effects in preclinical studies in a wide range of cancer cells and some animal models, and distinct signaling pathways are implicated in these results.Keep in mind that there are many other kinds of medicines and therapies that can help manage these effects as well.The presence of CBD may mitigate some of the psychoactive effects of THC and reduce its potential for abuse, but this varies depending on the ratio of THC to CBD and other factors.In the setting of this trial, THC and CBD showed promise as an add-on therapy for patients whose nausea and vomiting aren’t controlled by standard medications.Hanifa M, Wulandari R, Zulfin UM, Nugroho EP, Haryanti S, Meiyanto E. Different cytotoxic effects of vetiver oil on three types of cancer cells, mainly targeting CNR2 on TNBC.We do not see patients in Guernsey or Jersey.CBN is reported to have mild psychoactive effects, but they are in general much weaker than those of THC; its psychoactive effects are often considered a result of its partial agonism at CB1 receptors .It will compare efficacy and safety outcomes of a titrated dose (10 mg/10 mg/mL oral solution formulation, dose range 2.5 mg/2.5 mg-30 mg/30 mg/day) against placebo.Using a cross-over design, randomising patients to either study drug followed by placebo or placebo followed by study drug, will have 80% power at a two-sided significance level of 10% to detect a 20% difference in discordant responses (response on one intervention, but not the other). Anti-inflammatory effects were observed through the inhibition of protein denaturation (IC50 ∼350 μg/mL) and membrane stabilization (IC50 185–470 μg/mL, depending on the assay). This study examined the phytochemical composition and biological activities of Cannabis sativa L. This study was supported by the Bhumibol Adulyadej Hospital Research Fund granted in 2021. The short dose titration was tolerated in 86% receiving nabiximols, with one patient discontinuing because of transient psychiatric effects. Participants received up to 8.1 mg THC/7.5 mg CBD over 2 hours, then up to 21.6 mg THC/20 mg CBD every 24 hours for 5×24-hour periods. Cannabidiol and Delta-9-tetrahydrocannabinol interactions in male and female rats with persistent inflammatory pain. In Handbook of cannabis and related pathologies. Repeated treatment with cannabidiol but not Δ9-tetrahydrocannabinol has a neuroprotective effect without the development of tolerance. Driving was not permitted for legal reasons during study treatment or for 3 days after. The primary end point was the proportion of participants with complete response during h from chemotherapy. To date, 49 patients have been enrolled, with anticipated pilot study enrolment completion by the third quarter 2018. To help relieve pain for people who haven’t used cannabis in the past, experts recommend low-dose, non-inhaled cannabis products to start. It has been found to be most effective for cancer pain and for nerve (neuropathic) pain. Studies show mixed results in how effective cannabis is for pain in general. What symptoms and side effects can cannabis treat? All participants had received at least one cycle of the same chemotherapy before enrollment; 46% had received two or more cycles. Efficacy analyses were by intention to treat among all patients with available data and included participants who received the intervention for cycle A. In addition to the study treatment, all participants received guideline-recommended CINV prophylaxis (as described above), including a corticosteroid and a 5-HT3 antagonist, and where indicated, an NK-1 inhibitor and olanzapine. Patients must have experienced refractory CINV (defined as emesis and/or nausea of at least moderate severity on a five-point rating scale and/or requiring the use of rescue medications) in an earlier treatment cycle of the same chemotherapy regimen, despite eviQ14 and/or MASCC3,15 guideline-consistent antiemetic prophylaxis including a corticosteroid, 5-HT3 antagonist, and NK-1 antagonist, with or without olanzapine. Thirty-one percent experienced moderate or severe cannabinoid-related adverse events such as sedation, dizziness, or disorientation, but 83% of participants preferred cannabis to placebo. It discusses the pharmacology of cannabinoids, their mechanisms of action in modulating pain perception, and the potential therapeutic applications of cannabinoids in various pain conditions, including chronic pain, neuropathic pain, and inflammatory pain . Pergolizzi et al. review article discusses the potential of cannabinoids as analgesic agents in pain management. It discusses the evidence from clinical trials and observational studies regarding the efficacy and safety of cannabinoids, including THC and CBD, in various pain syndromes, such as neuropathic pain, fibromyalgia, and cancer-related pain . Medical By visiting this website and accessing this information you confirm that you are a healthcare professional. Educational content on VJOncology is intended for healthcare professionals only. Dizziness and sedation were the major side effects. Fifty-nine (21/54) percent cases were the advanced stages of cancer. Additionally, THC products should adhere to state-specific rules, potentially requiring a special prescription to curb misuse . Moreover, the absence of pharmacovigilance rules for online CBD products hinders the reporting of new side effects 70,74. Integrating cannabis-derived medicines has been challenging, with the first formulation approved in 2010—Sativex®. Five studies were included in the meta-analysis (1442 participants). • Providers should focus indications, alternatives, risks and benefits of medical cannabis use to make appropriate referrals. • Each state has its own regulations for medical and recreational cannabis use. H i g h l i g h t s • Tetrahydrocannabinol (THC), cannabidiol (CBD) and cannabinol (CBN) affect the human endocannabinoid system. The specific container was given to subjects before each cycle of chemotherapy. Therefore, the antiemetic-free duration between chemotherapy cycles was considered a washout period. The chemotherapy session was separated between cycle at least 21 days. All participants provided informed consent to receive standard antiemetic medication that included 20 mg dexamethasone, 8 mg ondansetron, and 50 mg ranitidine which were injected 30 min before chemotherapy administration. Todaro B. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting. In the realm of cancer treatment support, cannabinoids have demonstrated antineoplastic effects by inhibiting tumor growth and metastasis, although further research is necessary to optimize treatment protocols. Moreover, cannabinoids hold potential in the treatment of neurological disorders such as epilepsy, multiple sclerosis, Parkinson’s disease, and Alzheimer’s disease, offering neuroprotective and anti-inflammatory effects. The present study evaluated the in vitro protein denaturation inhibitory effects of two Cannabis sativa L. Consequently, a substance’s ability to inhibit protein denaturation implies potential anti-inflammatory effects. Their study also demonstrated that pure CBD exhibited stronger antioxidant activity than pure THC in the DPPH assay, while THC showed greater antioxidant potential in the ABTS test. The synergistic interplay between phenolic compounds and cannabinoids may contribute to the extract’s pharmacological activities. The antioxidant potential of the cannabis extracts was evaluated using the ABTS radical scavenging assay, adapted from Zouhri . To improve tolerance, we used a combination of THC with CBD, and allowed dose titration starting the day before each chemotherapy cycle. Putting the results of our study in context, Table 5 outlines the comparative efficacy of antiemetics versus placebo in positive randomized placebo-controlled trials. No vomiting or retching and no use of rescue medications during the overall phase of cycle A (0-120 hours). The control treatment was a placebo, presented in white capsules that were identical to that of the active treatment, and also produced by Tilray. • Combining Cannabis with conventional cancer treatment modalities may cause enhancing or diminishing effects. And its derivatives and analogues, known as cannabinoids (CBs), induce many effects throughout the whole body. Recently, in vitro and in vivo evidence support the effectiveness of phytocannabinoids against various cancer types, in terms of proliferation, metastasis, and angiogenesis, action... There is continuous research on phytocannabinoids and the Cannabis plant, and knowledge about its possible medical uses is expanding. Its full agonism at 5-HT1A serotonin receptors and transient receptor potential vanilloid 1 (TRPV1) channel contributes to its anxiolytic and analgesic effects (Figure 2). The intricate interactions and roles within the ECS make the pharmacological modulation of phytocannabinoids a compelling avenue for therapeutic exploration 11,12. CB2 receptor effects, whether standalone or influenced by co-activation with CB1, are protective, anti-inflammatory, regenerative, and antioxidant, presenting potential benefits in oncological therapy . Introduction Chemotherapy-induced nausea and vomiting (CINV) remains an important issue for patients receiving chemotherapy despite guideline-consiste...... Nausea and vomiting are among the most common side effects reported by people getting cancer treatment. People who have certain symptoms of cancer or side effects of cancer treatment might benefit from using cannabis. These effects are mediated through interactions with the endocannabinoid system, which plays a crucial role in regulating immune responses and inflammation throughout the body . Pharmacological profiles of the main phytocannabinoids mentioned above are summarized concisely in Table 1. CBN has been suggested to have sedative properties and may contribute to the sleep-inducing effects of certain cannabis strains; some studies indicate that CBN, when combined with THC, may enhance sedation. CBN interacts with the ECS but its interaction with the ECS is believed to be less potent than that of other cannabinoids. In Thailand, the Narcotics Act (N0.7) of 2019 allows the use of cannabis for medical treatment under the supervision of licensed physicians. Accordingly, the blockade of CB1 cannabinoid receptors induces vomiting. Platinum-based chemotherapy (cisplatin and carboplatin) were the backbone of chemotherapy regimen in gynecologic cancer and were classified as high emetic risk. Study finds starting chemotherapy within 6 weeks after colorectal cancer surgery improves survival rates. Long-term study shows pembrolizumab's superior efficacy over ipilimumab for advanced melanoma patients. Hanifa M, Wulandari R, Zulfin UM, Nugroho EP, Haryanti S, Meiyanto E. Different cytotoxic effects of vetiver oil on three types of cancer cells, mainly targeting CNR2 on TNBC. Adverse events for cycle B (in part after unblinding and crossover) were similar and are included in Appendix Table A3. Because of the high rates of crossover in the phase III component of the trial, efficacy results for cycle B and cycle C have not been analyzed. The only death was from febrile neutropenia in the placebo group. Studies indicate that cannabinoids can exert antitumor effects directly by inhibiting cell proliferation and inducing apoptosis, or indirectly by inhibiting angiogenesis, invasion, and metastasis. In recent years, research has increasingly focused on evaluating the potential of cannabinoids as antineoplastic agents. While some findings suggest that cannabinoids may have mood-stabilizing effects and enhance serotonin signaling, the evidence is inconclusive, and further research is warranted . Preclinical and clinical studies have explored the antidepressant potential of cannabinoids, primarily CBD and THC. It is crucial to note the wide array of CBD products available online and onsite, ranging from CBD oils in various concentrations (5–30%) to diverse cosmetic and daily care items like toothpaste and pain relief gel. Therefore, significant legislative modifications are necessary to establish appropriate prescription protocols and potentially reclassify the active pharmaceutical ingredient to a less restrictive schedule in some countries . Countries that have legalized cannabis often establish regulatory frameworks to oversee its production, distribution, and sale. Due to its composition and the psychoactive effects of THC, many countries have imposed strict regulations on its use, making it challenging to access for therapeutic purposes. Additionally, its activation of 5-HT1A receptors has demonstrated therapeutic effects in diabetic neuropathy and accelerated wound healing in diabetic rat models, thereby protecting vascular endothelial growth factor. However, the evidence is mixed, and more research is needed to clarify the role of cannabinoids in anxiety treatment . Vučković et al. provide an update on the research regarding the use of cannabinoids in pain management. Russo’s review article provides an overview of the role of cannabinoids in managing difficult-to-treat pain conditions. 3.6 HPLC-DAD analysis While overall the trial reduced CINV, the placebo arm had more patients receiving anthracycline (38% vs 24%), which is classified as highly emetogenic, potentially confounding the results.The mean age of participants was 54.4 years.The pilot study (crossover) and definitive trial (parallel) will use different methods of analysis as outlined in the statistical analysis section.Currently, no effective therapies are available for CIPN prevention, and symptomatic treatment is frequently ineffective; thus, several clinical trials are addressing this unmet clinical need.Due to its composition and the psychoactive effects of THC, many countries have imposed strict regulations on its use, making it challenging to access for therapeutic purposes.Study recruitment was closed early because of slow accrual without knowledge of differences in study outcomes between treatment arms for cycle A.The complex interaction between phytocannabinoids and biological systems offers hope for novel treatment approaches and lays the groundwork for further developments in the field of cannabinoid-based medicine.Given the limited availability of prescription pharmaceutical products authorized by regulatory bodies such as the FDA and EMA, there exists significant potential for stable CBD products to enter the pharmaceutical market. CBD is generally considered to have a low potential for abuse and dependence, and THC-containing cannabis products pose a greater risk, particularly when used chronically or in high doses . The presence of CBD may mitigate some of the psychoactive effects of THC and reduce its potential for abuse, but this varies depending on the ratio of THC to CBD and other factors. Research suggests that CBD may even have potential therapeutic effects in reducing addiction to other substances, such as opioids, alcohol, or nicotine . These psychoactive effects can contribute to its potential for abuse, as individuals may seek out the pleasurable sensations induced by THC consumption . Standardizing the terpene profile helps maintain consistency in sensory attributes and may also impact the “entourage” effect—the synergistic interaction between cannabinoids and terpenes 9,78. We used a pharmaceutical-grade oral capsule formulation to improve accuracy and convenience of dosing, in comparison with cannabis oil or inhaled cannabis products. Cultural barriers to implementation, including the unwillingness of oncologists to endorse or prescribe cannabis, is another challenge. The commonest reasons for screen failure were current use of prescribed or nonprescribed cannabis (the former is now more easily available in Australia), aversion to cannabis, and the need to restrict driving. CBD’s full agonism at adenosine A1 receptors potentially benefits cardiac arrhythmias and myocardial ischemia/reperfusion injuries. CBD acts as an antagonist for cannabinoid CB1 and CB2 receptors, while also inhibiting endocannabinoid degradation through the fatty acid amide hydrolase (FAAH) enzyme, leading to increased endocannabinoid levels and subsequent receptor activation. Responsible for numerous physiological effects within the ECS, CB1 and CB2 receptors are distributed in both the central nervous system (CNS) and peripheral tissues. Of the nine studies reviewed, eight reviewed the effect of the cannabinoid THC on cancer pain, and one study reviewed the use of medicinally available whole plant cannabis. REVIEW METHOD Articles reviewed address the use of cannabinoids or cannabis for pain management in oncology patients, either as stand- alone or adjuvant therapy. However, this evidence is not sufficient on its own to suggest THC and CBD is an effective treatment for chemotherapy-induced nausea and vomiting. Our trial did not provide information about longer-term efficacy over multiple cycles of chemotherapy because many participants completed chemotherapy within one or two cycles of study treatment. Pharmacological foundations of cannabis chemovars authors. Molecular docking further elucidated the mechanisms by which these extracts may exert their anti-inflammatory effects, particularly through NF-κB inhibition and anti-lipoxygenase activity. The hexane and chloroform extracts, in particular, demonstrated substantial bioactivity across various in vitro assays, reinforcing their therapeutic potential. Over the past few decades, numerous studies have investigated the anti-inflammatory effects of pure THC, CBD, and their combination. Given the structural similarity between human RBC membranes and lysosomal components, the inhibition of hemolysis under these conditions serves as a potential indicator of the extract’s anti-inflammatory mechanism. Is Maggie Beer Hemp Gummies Australia Really Works Side Effects Scam Updated 2022 The ECS is a sophisticated signaling system that is essential for controlling several physiological functions, including mood, hunger, sleep patterns, the immune system, and pain perception. As global perspectives on Cannabis continue to evolve, ongoing research and exploration of its diverse properties are shaping our understanding and expanding the potential applications of this remarkable plant 3,4. CBD is a non-psychoactive compound, which exhibits potential anti-inflammatory, neuroprotective, and anxiolytic properties, making it a promising candidate for a wide array of medical conditions. Cannabinoids represent a valuable option for treating CINV, despite the adverse events related to treatment, such as drowsiness and cognitive impairment. Poison control centers said children are getting sick after accidentally ingesting THC-infused edibles, as the market for THC containing products like hemp gummies is skyrocketing.#poisoncontrol #thcgummies #news #abcnews The oil I got my husband, was $75 for a CBD/THC Tincture which he WOULD’VE NEVER EVER EVEN TRIED, but was in massive pain!!Research indicates that NSAIDs inhibit FAAH activity, leading to enhanced ECS activity, which may contribute to the analgesic and anti-inflammatory effects of ibuprofen.They modulate pain perception through their interactions with cannabinoid receptors and other neurotransmitter systems involved in pain processing .While the overall risk of addiction to THC is lower compared to substances like opioids, amphetamines, or alcohol, it is still a concern, particularly for individuals who use cannabis frequently or in high doses 16,80.Adverse events such as dizziness, diarrhoea, fatigue, nausea, headache and somnolence occur quite frequently with nabiximols, but they are generally of mild-to-moderate intensity and their incidence can be markedly reduced by gradual uptitration.However, some experts don’t recommend using cannabis on a long-term basis because it may have a negative effect on the quality of your sleep.Factors such as genetic predisposition, underlying mental health conditions, environmental influences, and patterns of use all play a role in determining an individual’s risk of developing problematic cannabis use 5,7. • Conflicting reports show that Cannabis contains immunosuppressive properties and oncogenic potential. Finally, side-effects, limitations in trial design and legislation barriers are related. Moreover, immunological and antineoplastic effects in preclinical and clinical trials are addressed. Regulatory approvals have been gained across a broad range of palliative and therapeutic indications, and in some cases, included in standard treatment guidelines. However, central and peripheral (including GI) side effects may occur upon acute and chronic CB administration. These cannabinoids are often categorized alongside the plant itself or THC, the compound responsible for the addictive effects, particularly when found in higher concentrations in parts such as leaves and flowers. Franze et al. designed liposomal formulations with lidocaine and CBD in fixed combination to evaluate their potential in neuropathic pain treatment. Recent advancements include the growing recognition of the therapeutic potential of minor cannabinoids beyond CBD and THC, such as CBG, CBN, and CBC. Historically, research dating back to the 1970s has demonstrated the antineoplastic activity of cannabinoids in various cancer models. Studies have linked cannabinoids to the inhibition of cancer cell growth in several cancers, often through cell-specific mechanisms. In Australia, the study will be conducted according to the Note for Guidance on Good Clinical Practice (CPMP/ICH/135/95) annotated with Therapeutic Goods Administration Drug Safety and Evaluation Branch comments (July 2000) and in compliance with applicable laws and regulations. In addition, we will conduct a sensitivity analysis to determine the incremental costs to achieve an outcome of no significant nausea, no emesis and no use of rescue medications. Analyses to assess period by treatment interaction will use generalised estimating equations (GEEs) to account for the correlation within a patient. The primary analysis will be a comparison of the proportion of patients with a complete response between the two treatments over cycle A and cycle B, using McNemar’s test. The 20% difference is based on the assumption that 42% of patients on the study drug will respond compared with 22% on placebo, and that the responders in the placebo group will respond/not respond equally on the study drug (11% respond on each). Using a cross-over design, randomising patients to either study drug followed by placebo or placebo followed by study drug, will have 80% power at a two-sided significance level of 10% to detect a 20% difference in discordant responses (response on one intervention, but not the other). During the study period, the use of cannabis-related products was a major concern among the Thais, given the new Thai narcotic act. One-third of participants in the current study reported dizziness and sedation. Both groups (CX and placebo) had comparable side effects. Most cases (54/54) received platinum-based chemotherapy regimen. During the study period, 60 patients were enrolled and divided into groups A and B. Clinical Trial: Cannabis Extracts Effective for Refractory Chemotherapy-Induced Nausea Terpenes are aromatic compounds found in Cannabis that contribute to its flavor and aroma, as well as potential therapeutic effects. Standardization involves accurately measuring and labeling the content of major cannabinoids such as CBD and THC. The laws and regulations governing phytocannabinoids are subject to change as scientific understanding evolves, public attitudes shift, and policymakers respond to emerging issues and challenges. This has led to prohibitions and stringent legislation, hindering patients’ ability to utilize the plant for medical treatment 7,15. The legal and regulatory issues surrounding phytocannabinoids, particularly compounds like CBD and THC, are complex and vary widely across different jurisdictions. Phytocannabinoids offer diverse therapeutic applications, ranging from pain management to neurological disorders and inflammatory diseases. Looking ahead, ongoing research and trials continue to explore the therapeutic potential of phytocannabinoids, including minor cannabinoids beyond CBD and THC. Despite these challenges, there is a growing recognition of the therapeutic potential of phytocannabinoids, particularly CBD and THC, in treating various medical conditions. Additionally, cannabinoids demonstrate antioxidant effects, which can mitigate oxidative stress and contribute to the management of cardiovascular, neurodegenerative, and metabolic disorders. Their anti-inflammatory effects mediated through interactions with the ECS offer potential treatments for inflammatory diseases, autoimmune conditions, and neuroinflammation. Secondary end points included self-reported complete response, no emesis (vomiting or retching), no use of rescue medications, no clinically significant nausea (20 and by participants using a trial-specific structured checklist of self-rated adverse events of special interest, including dizziness, disorientation, hallucinations, anxiety, palpitation, and sedation. Health economic analyses will be reported separately in the future. Health-related quality of life (HRQL) outcome measures included the Functional Living Index—Emesis (FLIE)18 and the Assessment of Quality of Life—eight dimensions (AQOL-8D),19 a multiattribute utility instrument, completed at baseline, day 6 of each cycle, and at days after the last dose of study treatment. Participants underwent clinical assessment by the study investigator on day –1 of cycles A, B, and C, and at 30 to 42 days after the last dose of study treatment. REVIEW METHOD Articles reviewed address the use of cannabinoids or cannabis for pain management in oncology patients, either as stand- alone or adjuvant therapy.Cannabinoids express their effects through two types of receptors, cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2).The report went on to recognize that patients should be allowed to smoke marijua- na ifAbout 39% reported previous cannabis use, and 65% were being treated with curative intent.The biosynthetic pathway involves enzymes that convert precursor compounds into various phytocannabinoids .Indeed, phytocannabinoids mimic the endogenous bioactive endocannabinoids effects through activation of CB1 and CB2 receptors widely described in the central nervous system and peripheral tissues.CBC interacts with ECS, but its affinity for CB1 and CB2 receptors is relatively low compared to cannabinoids like THC . CBG stands out as it can be produced by certain hemp chemotypes without residual THC, making it a potentially excellent and safe antiseptic agent. The mechanisms for these activities are not fully understood, as cannabinoid receptors interfere with various intracellular signaling pathways. Cannabinoids intervene in tumor cell development cycles, inhibit growth, induce apoptosis, and reduce tumor cell migration and angiogenic activity. The aim of this paper is to conduct a systematic review and meta-analysis of the efficacy and safety of oral cannabinoids compared with other treatments as documented in randomized controlled trials (RCTs). Although the effectiveness of cannabinoids is limited, it was confirmed in neuropathic pain management and combination with opioids. Cannabinoids have been shown to be of benefit in the treatment of HIV-related peripheral neuropathy, suggesting that they may be worthy of study in patients with other neuropathic symptoms. Cannabinoids may be of benefit in the treatment of cancer-related pain, possibly synergistic with opioid analgesics. A Closer Look at the Clinical Trial It explores the antioxidant and anti-inflammatory properties of cannabinoids and their potential as therapeutic agents for CNS inflammation and neurodegeneration . Jackson et al. also discussed the neuroprotective effects of cannabinoids in CNS inflammatory diseases, such as multiple sclerosis, Alzheimer’s disease, and stroke. It explores the antioxidant and neuroprotective properties of cannabinoids, including THC and CBD, and their potential as therapeutic agents for neurodegeneration . Scotter et al. outlined the potential of targeting the endocannabinoid system for the treatment of neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease. It discusses the anti-inflammatory properties of cannabinoids and their potential therapeutic applications in rheumatoid arthritis, osteoarthritis, and other rheumatic conditions, highlighting the need for further research in this area . Group A received CX (labeled as “Cycle 1”) in the first chemotherapy cycle and received placebo 30 min before chemotherapy (labeled as “Cycle 2”) in the next chemotherapy cycle (consequent cycle). CINV is one of the most common adverse effects and leads to significant morbidity and deterioration of patients’ quality of life.1 As a consequence, noncompliance to chemotherapy treatment can be frequently observed.2,3 No definitive trials have been conducted to support the use of cannabinoids for this indication, nor has the potential economic impact of incorporating such regimens into the Australian healthcare system been established. In the second cycle, groups A and B received placebo and TCEO before chemotherapy administration. Patients with gynecologic malignancies treated with moderate-to-high emetogenic chemotherapy at Bhumibol Adulyadej Hospital were enrolled. The study was conducted in accordance with the Declaration of Helsinki. This was a randomized, double-blinded, crossover, placebo-controlled trial. There are now over 700 varieties of cannabis from which hundreds of compounds have been identified. Cannabinoid therapies are varied and versatile, and can be offered as pharmaceuticals (nabilone, dronabinol, and nabiximols), dried botanical material, and edible organic oils infused with cannabis extracts. Using the 15 mg/m 2 dose, all patients experienced transient sensorial changes, characterized as a pleasant "high" in 19 or a variable state of dysphoria in 17 cases. THC efficacy was not dependent on the class of antineoplastic-agent inducing the emetic symptoms, age of patients or type of sensorial change experienced. Pilot study When controlling for vomiting, oral cannabinoid was equally as efficacious as others. Evidence suggests that cannabinoid CB2 receptors are present in brainstem neurons, and thus, there may exist a role for cannabinoids to counter CINV. A relatively favorable adverse effects profile, including no depressive effect on the respiratory system, may make cannabis complement a rather narrow armamentarium that is in the disposition of a palliative care professional. There is increasing interest in the use of medicinal cannabinoids but little high-quality evidence to guide clinicians. Additional parameters evaluated were study drug effects on appetite, food intake, mood, activity, relaxation, interaction, and concentration. Pharmacological Profiles of Key Phytocannabinoids The estimated sample size for the definitive trial is 250 patients (125 per arm), using a primary endpoint of complete response during cycle A of study treatment. Chemotherapy-induced nausea and vomiting (CINV) remains a significant cause of morbidity in oncology patients despite the best current antiemetic prophylaxis.1 Half of the subjects in their study received high-emetogenic agent (platinum-based), whereas all patients in our study underwent high-emetogenic chemotherapy. Group B received placebo 30 min before chemotherapy (“Cycle 1”) in the first chemotherapy cycle and received CX (labeled as “Cycle 2”) in the next chemotherapy cycle. Rescue medications were to be used for nausea or vomiting that occurred during the study as per standard guidelines.14,15,17 During the subsequent phase III component of the trial, which used a parallel design, participants were to continue the same treatment for cycle B and cycle C (but following a protocol amendment to enhance recruitment, were allowed to choose the alternative treatment if they experienced significant CINV during cycle A). During the initial phase II component of the trial, which used a crossover design, participants were treated with the alternative treatment for cycle B, then nominated their preferred treatment for cycle C. Eligible patients were age 18 years and older with a solid tumor or hematologic malignancy of any stage, being treated with intravenous chemotherapy of moderate or high emetogenic risk, and scheduled for at least two more consecutive cycles of the same chemotherapy. The plant’s diverse chemical composition, which includes over 565 identified compounds such as cannabinoids, terpenes, and flavonoids, underpins its therapeutic potential 7,8,9.One-third of participants in the current study reported dizziness and sedation.This has led to prohibitions and stringent legislation, hindering patients’ ability to utilize the plant for medical treatment 7,15.The aim of this paper is to conduct a systematic review and meta-analysis of the efficacy and safety of oral cannabinoids compared with other treatments as documented in randomized controlled trials (RCTs).Participants received up to 8.1 mg THC/7.5 mg CBD over 2 hours, then up to 21.6 mg THC/20 mg CBD every 24 hours for 5×24-hour periods.Recent findings on the anti-inflammatory and analgesic properties of CB2 receptors hold potential for treating diseases linked to ECS activation.Eligible patients were age 18 years and older with a solid tumor or hematologic malignancy of any stage, being treated with intravenous chemotherapy of moderate or high emetogenic risk, and scheduled for at least two more consecutive cycles of the same chemotherapy. The plant’s diverse chemical composition, which includes over 565 identified compounds such as cannabinoids, terpenes, and flavonoids, underpins its therapeutic potential 7,8,9. The placebo effect and fixed doses of cannabinoid were an unavoidable limitation of the study. Dizziness and sedation are not serious side effects for patients with cancer. The current study enrolled patients with gynecologic malignancy who underwent high-emetogenic chemotherapy. It has over 540 metabolites thought to be responsible for its therapeutic effects. It will compare efficacy and safety outcomes of a titrated dose of CBD (100 mg/mL formulation, dose range 50 mg to 600 mg per day) against placebo. Introduction If you’ve ever enjoyed the piney aroma of a cannabis flower or noticed... In rats, CBDA (0.01 and 0.1 mg•kg-1 i.p.) suppressed LiCl-and context-induced conditioned gaping, effects that were blocked by the 5-HT1A receptor antagonist, WAY (0.1 mg•kg-1 i.p.), and, at 0.01 mg•kg-1 i.p., enhanced saccharin palatability. KEY RESULTS In shrews, CBDA (0.1 and/or 0.5 mg•kg-1 i.p.) reduced toxin-and motion-induced vomiting, and increased the onset latency of the first motion-induced emetic episode. It will compare efficacy and safety outcomes of a titrated dose (10 mg/10 mg/mL oral solution formulation, dose range 2.5 mg/2.5 mg-30 mg/30 mg/day) against placebo. Neither past marijuana use nor past Compazine use were related to study drug efficacy. Two hundred and fourteen subjects (75% of whom had previously received Compazine with varying results) were evaluated employing a double-blind, crossover design. Both drugs were administered orally one hour before chemotherapy, then every four hours for a total of four doses. Patients with malignant disease, at all points of their disease trajectory, could be candidates for cannabinoid therapies whether as monotherapies or as adjuvants. Seventy percent (5/7) of Duran’s cases reported good effect and the side effects of Duran’s reported were 86%.15CBG stands out as it can be produced by certain hemp chemotypes without residual THC, making it a potentially excellent and safe antiseptic agent.CINV is one of the most common adverse effects and leads to significant morbidity and deterioration of patients’ quality of life.1 As a consequence, noncompliance to chemotherapy treatment can be frequently observed.2,3Both drugs were administered orally one hour before chemotherapy, then every four hours for a total of four doses.Consequently, CBDA shows promise as a treatment for nausea and vomiting, including anticipatory nausea for which no specific therapy is currently available.Despite these challenges, there is a growing recognition of the therapeutic potential of phytocannabinoids, particularly CBD and THC, in treating various medical conditions.H i g h l i g h t s • Tetrahydrocannabinol (THC), cannabidiol (CBD) and cannabinol (CBN) affect the human endocannabinoid system.The product is intended to provide equivalent systemic exposures to THC and CBD as nabiximols and was formulated for a consistent and reproducible pharmacokinetic profile, allowing patients to self-titrate as needed without a concern for a delayed onset.Yekhtin et al. found that cannabis extracts had a greater inhibitory effect on cytokine secretion compared to pure cannabinoids . From the more than one hundred cannabinoids which were identified in the Cannabis plant so far, cannabidiol (CBD) and tetrahydrocannabinol (THC) are two of the most extensively studied phytocannabinoids. This comprehensive review presents the intricate pharmacological profiles of phytocannabinoids while exploring the diverse impacts these substances have on biological systems. More studies are still needed to evaluate the effectiveness of cannabinoids when compared with modern antiemetics. There is no good quality evidence to recommend or not the use of cannabinoids for CINV. Phytocannabinoids refer to a group of oxygenated aromatic hydrocarbon metabolites derived from the Cannabis plant that contain 21 carbon atoms. The term cannabinoid refers to both natural cannabinoids (endocannabinoids, phytocannabinoids) and synthetic cannabinoids that operate on cannabinoid receptors. The biosynthetic pathway involves enzymes that convert precursor compounds into various phytocannabinoids . According to NICE it can be considered by NHS doctors as an add-on treatment when CINV persists despite first-line treatments. There is already a licensed medical cannabis product for CINV called Nabilone. In addition to having anxiolytic properties, some evidence indicates that CBD may be able to reduce some of the neuropsychiatric effects of THC. CINV is mediated by several pathways linked to serotonin, dopamine, substance P, and cannabinoid receptors. This not only drastically impacts a patient’s quality of life but in some cases can also lead them to stop treatment altogether.